AI can process and interpret scientific data with meaningful capability, but not with the reliability or contextual judgment that medical communications demands. The tools available in 2026 can handle structured datasets, synthesise published literature, and generate draft content at pace — but they require expert human oversight to ensure accuracy, regulatory alignment, and scientific integrity. The questions below unpack where AI adds genuine value, where it falls short, and how responsible medcomms teams should be working with it.
Can AI accurately interpret clinical trial data?
AI can extract, summarise, and identify patterns within clinical trial data, but accurate interpretation is a more complex challenge. Large language models and specialist AI tools can process trial results, flag statistical relationships, and generate narrative summaries — but they lack the clinical judgment to contextualise findings within a therapeutic area, patient population, or evolving evidence base.
That distinction matters enormously in medical writing. A result that appears statistically significant may be clinically modest, or meaningful only when read alongside a specific comparator arm. AI tools trained on general or biomedical literature may miss these nuances or, more dangerously, present them with unwarranted confidence. For AI-assisted scientific data handling to be reliable in a clinical context, outputs must be reviewed by medical writers or clinicians who understand both the data and its strategic implications.
That said, AI performs well in structured, defined tasks: extracting primary and secondary endpoints, organising patient subgroup data, or flagging inconsistencies across multiple trial documents. Used as a first-pass tool rather than a final authority, it can meaningfully accelerate the work of experienced medcomms professionals.
What types of scientific data can AI process in medical writing?
AI medical writing tools can process a broad range of scientific data types, including published clinical trial results, systematic reviews, meta-analyses, regulatory submission documents, real-world evidence datasets, and structured pharmacovigilance data. The quality of processing depends heavily on whether the data is structured, standardised, and drawn from sources the model has been trained on or can access.
In practical medcomms workflows, AI is most reliably applied to:
- Summarising published literature and generating evidence tables
- Drafting slide content from structured data outputs
- Identifying relevant publications across a therapeutic area
- Extracting key data points from clinical study reports
- Supporting language translation and localisation of scientific content
- Generating first drafts of standard medical education materials
AI becomes less reliable when processing unstructured, ambiguous, or highly specialised data — early-phase biomarker studies, complex adaptive trial designs, or niche biological mechanisms that are underrepresented in training data. In these areas, the risk of misinterpretation or oversimplification increases substantially.
How does AI verify the accuracy of scientific claims?
It doesn’t — not in the way a human expert does. Most AI tools generate content by predicting plausible outputs based on patterns in their training data, which means they can produce confident-sounding statements that are factually incorrect, outdated, or imprecisely referenced. This is one of the most significant limitations for AI data accuracy in healthcare contexts.
Some tools incorporate retrieval-augmented generation (RAG), which allows them to search and cite specific source documents rather than relying solely on trained knowledge. This improves accuracy and traceability, but it does not eliminate the risk of misquotation, selective citation, or failure to recognise when a source has been superseded by newer evidence.
In practice, AI-generated scientific content requires a structured human review process that includes:
- Cross-checking every cited claim against the original source document
- Verifying that statistical data has been accurately extracted and contextualised
- Confirming that claims reflect the most current evidence, not outdated trial data
- Ensuring language meets regulatory and compliance standards for the relevant market
Treating AI as a drafting assistant rather than a fact-checker is the only responsible approach in medical communications, where an inaccurate claim carries genuine clinical and regulatory risk.
What are the risks of using AI with unpublished or proprietary data?
Using AI tools with unpublished or proprietary scientific data introduces serious risks around data security, intellectual property, and regulatory compliance. When confidential trial data, pre-submission regulatory documents, or proprietary research findings are entered into consumer-facing AI platforms, there is a real possibility that this information is retained, used for model training, or exposed through platform vulnerabilities.
For pharmaceutical companies and biotech clients, this is not a theoretical concern. Unpublished trial data is commercially sensitive, often subject to confidentiality agreements, and its premature disclosure can have significant consequences for regulatory timelines and competitive positioning. Medcomms agencies handling this type of material must apply strict governance around which AI tools are used, under what terms, and with what data.
Enterprise AI solutions with data isolation, private deployment, or documented data handling agreements offer a more appropriate environment for working with proprietary scientific information. Even then, the principle of minimum necessary data applies: AI tools should receive only the information required for the specific task, not full access to a client’s data environment.
Where does human oversight fit into AI-assisted medical content?
Human oversight is not an optional quality step — it is the foundation that makes AI use responsible and effective. In AI-assisted medical communications, the human role shifts from pure content generation to expert review, strategic direction, scientific validation, and regulatory judgment. These require domain knowledge that AI cannot replicate.
Effective oversight in an AI-assisted medcomms workflow typically involves medical writers who can critically assess AI-generated drafts for scientific accuracy; medical affairs or clinical reviewers who verify that content reflects current evidence and approved labelling; regulatory specialists who ensure compliance with applicable codes such as the ABPI Code in the UK or PhRMA guidelines in the US; and senior strategists who ensure the content serves the right audience with the right message.
The strongest medcomms teams use AI to handle high-volume, repeatable tasks, freeing expert time for the work that genuinely requires human judgment: interpreting ambiguous data, shaping scientific narrative, engaging external experts, and ensuring that complex information reaches its audience with clarity and impact.
Which AI tools are used for scientific data handling in medcomms?
The AI tools used for scientific data handling in medcomms span general-purpose large language models, specialist biomedical platforms, and purpose-built regulatory writing tools. The right choice depends on the specific task, the sensitivity of the data involved, and the governance requirements of the client and market.
Commonly used categories in 2026 include:
- General large language models (such as those from OpenAI, Anthropic, and Google) used for drafting, summarising, and structuring content from published sources
- Biomedical literature tools such as Semantic Scholar, Elicit, and Consensus, which are designed to search, summarise, and synthesise peer-reviewed evidence
- Regulatory writing platforms with AI-assisted features built specifically for clinical study reports, dossier preparation, and submission documents
- Internal enterprise AI deployments used by larger pharma companies and agencies under controlled data governance frameworks
- Medical affairs platforms that integrate AI for field medical team content, publication planning, and evidence gap analysis
No single tool handles all aspects of AI in medical content reliably. The most effective implementations layer multiple tools within a governed workflow, with clear human checkpoints at each stage.
How we approach AI in medical communications
At Wizzard, we integrate AI into medical communications work within a framework of expert human oversight and rigorous scientific review. Our medical writers and scientific strategists lead every project — AI supports drafting and literature review; it does not replace expert judgment.
- All AI-assisted content is reviewed against source documents for scientific accuracy and regulatory compliance
- Data governance is applied rigorously, particularly when working with proprietary or pre-publication client materials
- We combine scientific rigour with strategic and creative thinking to produce communications that genuinely serve the audience
If you are working with complex scientific data and need medical communications that are accurate and compelling, get in touch to talk through how we can help.